InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.240
+0.110 (5.16%)
Dec 20, 2024, 4:00 PM EST - Market closed
InflaRx Employees
InflaRx had 62 employees as of December 31, 2023. The number of employees increased by 18 or 40.41% compared to the previous year.
Employees
62
Change (1Y)
18
Growth (1Y)
40.41%
Revenue / Employee
$3,021
Profits / Employee
-$1,019,980
Market Cap
131.90M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
American Well | 1,104 |
Akoya Biosciences | 330 |
Protalix BioTherapeutics | 208 |
Enanta Pharmaceuticals | 145 |
Black Diamond Therapeutics | 54 |
Elutia | 54 |
Galectin Therapeutics | 14 |
Atossa Therapeutics | 12 |
IFRX News
- 1 day ago - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewsWire
- 5 weeks ago - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 6 weeks ago - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 3 months ago - InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewsWire
- 4 months ago - InflaRx Announces Participation in September Investor Events - GlobeNewsWire
- 4 months ago - InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewsWire